Efficacy and Safety of Etanercept 50 mg Once Weekly Plus As Needed Topical Agent in Moderate to Severe Plaque Psoriasis

A Randomized, Blinded Assessor Study to Evaluate the Efficacy and Safety of Etanercept 50 mg Once Weekly Plus As Needed Topical Agent Versus Etanercept 50 mg Twice Weekly in Subjects With Moderate to Severe Plaque Psoriasis

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01313221

Acronym

REFINE

Enrollment

310

Registered

2011-03-11

Start date

2011-04-30

Completion date

2013-05-31

Last updated

2017-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Keywords

plaque psoriasis, moderate, severe, etanercept, Enbrel, topical

Brief summary

To estimate the difference in effectiveness between treatment with etanercept 50 mg twice weekly (BIW) and treatment with etanercept 50 mg once weekly (QW) plus an as needed (PRN) topical agent for 12 weeks in adults with moderate to severe plaque psoriasis.

Detailed description

The recommended starting dose of etanercept for adult plaque psoriasis patients is a 50 mg dose given twice a week (BIW) for 3 months followed by a reduction to a maintenance dose of 50 mg once weekly (QW). While most patients with moderate to severe plaque psoriasis are managed satisfactorily on etanercept monotherapy, a proportion may require a modified or alternative treatment regimen (eg, to handle flares or loss of effect) at some point during their chronic management. Despite the clinical need, no published data from randomized controlled studies are currently available that demonstrate efficacy and safety of combined etanercept-based regimens in patients with plaque psoriasis. The addition of an as-needed topical medication to the step-down dose of etanercept 50 mg once weekly administered after the initial 12 week period of 50 mg twice weekly may be a potential option for patients who may require adjunctive therapy. This study aimed to provide data on this treatment option by estimating the difference in mean percent change in Psoriasis Area and Severity Index (PASI) scores between step-down etanercept 50 mg once weekly supplemented with as-needed topical medication and continuous treatment with etanercept 50 mg twice weekly. Eligible patients will be enrolled in the study and will receive etanercept 50 mg twice weekly for 12 weeks. After 12 weeks of etanercept treatment, participants will be randomized in a 1:1 ratio to 1 of 2 treatment groups.

Interventions

BIOLOGICALetanercept

Administered by subcutaneous injection

DRUGTopical agents

Topical agents prescribed at the discretion of the Principal Investigator and were are limited to the following: * hydrocortisone 2.5% * betamethasone valerate 0.1% * betamethasone dipropionate 0.05% * clobetasol 0.05% * calcitriol * calcipotriol plus betamethsone dipropionate 0.05%

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Has had stable moderate to severe plaque psoriasis for at least 6 months (eg, no morphology changes or significant flares of disease activity in the opinion of the investigator). * Has a body surface area (BSA) involvement ≥ 10% and Psoriasis Area and Severity Index (PASI) ≥ 10 at screening and at baseline. * Is a candidate for systemic therapy or phototherapy in the opinion of the investigator. * Other inclusion criteria may apply.

Exclusion criteria

* Has active guttate, erythrodermic, or pustular psoriasis at the time of the screening visit. * Has evidence of skin conditions at the time of the screening visit (eg, eczema) that would interfere with evaluations of the effect of etanercept on psoriasis. * Diagnosed with medication-induced or medication-exacerbated psoriasis. * Significant concurrent medical conditions. * Has any active localized infection; requiring local intervention or chronic or localized infections. * Other

Design outcomes

Primary

Measure	Time frame	Description
Percent Change in Psoriasis Area and Severity Index (PASI) From Week 12 to Week 24	Week 12 and Week 24	The Psoriasis Area and Severity Index (PASI) score is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from none (0), mild (1), moderate (2), severe (3) or very severe (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease. Change from Week 12 to Week 24 is presented as a percentage of the Week 12 value: Week 12 value - Week 24 value / Week 12 value \* 100 so that a positive change indicates improvement. Change was adjusted for treatment using a mixed model.

Secondary

Measure	Time frame	Description
Percent Change in PASI From Baseline to Weeks 12, 16, 20, and 24	Baseline and Weeks 12, 16, 20, and 24	The Psoriasis Area and Severity Index (PASI) score is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from none (0), mild (1), moderate (2), severe (3) or very severe (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease. Change from Baseline is presented as a percentage of the Baseline value: Baseline value - postbaseline value / Baseline value \* 100, so that a positive change indicates improvement.
Percentage of Participants With a PASI 50 Response	Baseline and Weeks 12, 16, 20 and 24	The percentage of participants with a 50% reduction (improvement) in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI score is based on an assessment of erythema (reddening), induration (plaque thickness), desquamation (scaling), and the percent area affected as observed on the day of examination. The score ranges from 0 (best outcome) to 72 (worst outcome).
Percentage of Participants With a PASI 75 Response	Baseline and Weeks 12, 16, 20 and 24	The percentage of participants with a 75% reduction (improvement) in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI score is based on an assessment of erythema (reddening), induration (plaque thickness), desquamation (scaling), and the percent area affected as observed on the day of examination. The score ranges from 0 (best outcome) to 72 (worst outcome).
Percentage of Participants With a PASI 90 Response	Baseline and Weeks 12, 16, 20 and 24	The percentage of participants with a 90% reduction (improvement) in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI score is based on an assessment of erythema (reddening), induration (plaque thickness), desquamation (scaling), and the percent area affected as observed on the day of examination. The score ranges from 0 (best outcome) to 72 (worst outcome).
Percentage of Participants With a Static Physician's Global Assessment (sPGA) of Psoriasis Score of 0 (Clear) or 1 (Almost Clear)	Weeks 12, 16, 20, and 24	The sPGA scale is completed by the same blinded assessor performing the PASI assessments and is designed to evaluate the physician's global assessment of the participant's psoriasis based on severity of induration, scaling, and erythema. The sPGA is assessed on a scale of 0 to 5 (0 = clear, 5 = severe).
Percent Change in the Percentage of Body Surface Area (BSA) Involvement From Week 12 to Weeks 16, 20, and 24	Weeks 12, 16, 20, and 24	The percentage of body surface area involved with psoriasis was measured by the same blinded assessor performing the PASI assessments. Change from Week 12 is presented as a percentage of the Week 12 value: Week 12 value - postbaseline value / Week 12 value \* 100, so that a positive change indicates improvement. Change was adjusted for treatment using a mixed model.
Percent Change in the Percentage of Body Surface Area (BSA) Involvement From Baseline to Weeks 12, 16, 20, and 24	Baseline and Weeks 12, 16, 20, and 24	The percentage of body surface area involved with psoriasis was measured by the same blinded assessor performing the PASI assessments. Change from Baseline \\ is presented as a percentage of the Baseline value: Baseline value - postbaseline value / Baseline value \* 100, so that a positive change indicates improvement.
Change From Week 12 to Week 24 in Dermatology Quality of Life Index (DQLI) Total Score	Week 12 and Week 24	The DLQI questionnaire asks participants to evaluate the degree that psoriasis has affected their quality of life in the last week, and includes the following parameters: symptoms and feelings, daily activities, leisure activities, work or school activities, personal relationships and treatment related feelings. Participants answer 10 questions on a scale from 0 (not at all) to 3 (very much); the range of the total score is 0 to 30. A score of 21 to 30 means an extremely large effect on the participant's life whereas 0-1 means that the disease has no effect at all. Change from Week 12 to Week 24 is calculated as: Week 12 value - Week 24 value so that a positive change indicates improvement. Change was adjusted for treatment using a mixed model.
Change From Baseline to Weeks 12 and 24 in Dermatology Quality of Life Index (DQLI) Total Score	Baseline and Week 12 and Week 24	The DLQI questionnaire asks participants to evaluate the degree that psoriasis has affected their quality of life in the last week, and includes the following parameters: symptoms and feelings, daily activities, leisure activities, work or school activities, personal relationships and treatment related feelings. Participants answer 10 questions on a scale from 0 (not at all) to 3 (very much); the range of the total score is 0 to 30. A score of 21 to 30 means an extremely large effect on the participant's life whereas 0-1 means that the disease has no effect at all. Change from Baseline was calculated as Baseline value - postbaseline value so that a positive change indicates improvement.
Change in Treatment Satisfaction Questionnaire for Medications (TSQM) Scores From Week 12 to Week 24	Week 12 and Week 24	TSQM is a validated questionnaire consisting of 14 questions regarding a participant's perception of the level of satisfaction or dissatisfaction with the medication they are taking. Four scales are generated: side effects, effectiveness, convenience, and global satisfaction. Optional responses are: Extremely Dissatisfied, Very Dissatisfied, Dissatisfied, Somewhat Satisfied, Satisfied, Very Satisfied, and Extremely Satisfied. From the responses, a scale score from 0 - 100 is calculated, with a higher score indicating greater satisfaction. Change was calculated as Week 24 - Week 12 so that a positive change indicates improvement over time. Change was adjusted for treatment using a mixed model.
Percent Change in PASI From Week 12 to Weeks 16 and 20	Week 12, Week 16 and Week 20	The Psoriasis Area and Severity Index (PASI) score is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from none (0), mild (1), moderate (2), severe (3) or very severe (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease. Change from Week 12 presented as a percentage of the Week 12 value: Week 12 value - postbaseline value / Week 12 value \* 100, so that a positive change indicates improvement. Change was adjusted for treatment using a mixed model.
Health Resource Utilization: Number of Participants With Visits to a Healthcare Provider	Baseline and 24 weeks	Participants completed a questionnaire to assess their health resource utilization (HRU) related to psoriasis. To assess the number of visits to a healthcare provider, participants answered the following questions regarding the past 4 weeks: How many times have you been to any physician's office or urgent care clinic? How many times have you seen a nurse practitioner, a physician assistant, a psychologist, a naturopath, an acupuncturist, a chiropractor, or other healthcare professional (HCP)? The number of participants with one or more visits is reported.
Health Resource Utilization: Number of Participants With Home Healthcare Visits	Baseline and 24 weeks	Participants completed a questionnaire to assess their health resource utilization (HRU) related to psoriasis. To assess the number of homecare visits, participants answered the following question regarding the past 4 weeks: How many times have you received care from a health professional in your home? The number of participants with one or more visits is reported.
Health Resource Utilization: Number of Participants Requiring Paid Help With Chores	Baseline and 24 weeks	Participants completed a questionnaire to assess their health resource utilization (HRU) related to psoriasis. To assess the number of participants who needed paid help with chores, participants answered the following question regarding the past 4 weeks: How many times have you paid someone to help you do chores around the house (cleaning, maintenance, lawn care)? The number of participants who paid for help one or more times is reported.
Health Resource Utilization: Number of Participants Who Needed Friend or Family Care	Baseline and 24 weeks	Participants completed a questionnaire to assess their health resource utilization (HRU) related to psoriasis. Participants answered the following question regarding the past 4 weeks: How many hours have you had a friend or family member take time off work to provide care or transportation? The number of participants who had paid or non-paid help for one or more hours is reported.
Health Resource Utilization: Out of Pocket Expenses	Baseline and 24 weeks	Participants completed a questionnaire to assess their health resource utilization (HRU) related to psoriasis. To assess out of pocket expenses, participants answered the following question regarding the past 4 weeks: Not counting study mandated visits, what out-of-pocket expenses did you spend for the management of psoriasis (i.e. costs due to travelling to doctor appointment, hospital or clinic parking costs, alternative medications)?
Health Resource Utilization: Employment Status	Baseline and 24 weeks	Participants completed a questionnaire to assess their health resource utilization (HRU) related to psoriasis. Participants were asked their employment status at Baseline and at Week 24.
Health Resource Utilization: Productivity While Working	Baseline and 24 weeks	Participants who were employed were asked: How much did your psoriasis affect your productivity while you were working? Possible responses were: a) A great deal; b) Quite a bit; c) Somewhat; d) Minimally; e) Not at all.
Health Resource Utilization: Number of Participants With Missed Hours From Work	Baseline and 24 weeks	Participants who were employed answered the following question regarding the past 4 weeks: How many hours per week did you miss from work because of your psoriasis? The number of participants with one or more missed hours of work per week is reported.
Health Resource Utilization: Ability to Perform Daily Activities	Baseline and 24 weeks	Participants were asked: How much did your psoriasis affect your ability to do your daily activities or household chores? Possible answers were: a) A great deal; b) Quite a bit; c) Somewhat; d) Minimally; e) Not at all.
Number of Participants With Adverse Events	32 weeks	An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant. A serious adverse event is defined as an adverse event that meets at least 1 of the following serious criteria: • fatal, • life threatening, • requires in-patient hospitalization or prolongation of existing hospitalization, • results in persistent or significant disability/incapacity, • congenital anomaly/birth defect, and/or • other significant medical hazard.
Change in Treatment Satisfaction Questionnaire for Medications (TSQM) Scores From Baseline to Weeks 12 and 24	Baseline and Weeks 12 and 24	The TSQM is a validated questionnaire consisting of 14 questions regarding a participant's perception of the level of satisfaction or dissatisfaction with the medication they are taking. Four scales are generated: side effects, effectiveness, convenience, and global satisfaction. Optional responses are: Extremely Dissatisfied, Very Dissatisfied, Dissatisfied, Somewhat Satisfied, Satisfied, Very Satisfied, and Extremely Satisfied. From the responses, a scale score from 0 - 100 is calculated, with a higher score indicating greater satisfaction. Change was calculated as postbaseline value - Baseline value so that a positive change indicates improvement.

Countries

Canada

Participant flow

Recruitment details

First patient enrollment :29 April 2011; last patient enrollment: 4 June 2012.

Pre-assignment details

A total of 414 patients were screened,310 patients were enrolled and 287 randomized in this study; 144 in the etanercept monotherapy group (group A) and 143 in the etanercept plus an as-needed topical agent group (group B). 23 patients were not randomized because they did not complete the 12-week open-label treatment period before randomization.

Participants by arm

Arm	Count
Etanercept 50 mg BIW Following 12 weeks of etanercept 50 mg twice weekly (BIW), participants were randomized to 50 mg etanercept by subcutaneous injection twice weekly for 12 weeks.	144
Etanercept 50 mg QW + Topical Following 12 weeks of etanercept 50 mg twice weekly, participants were randomized to 50 mg subcutaneous injection once weekly (QW) plus as needed topical agents.	143
Non-randomized Enrolled participants received etanercept 50 mg twice weekly but discontinued prior to completing the 12-week open-label treatment period.	23
Total	310

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002
Overall Study	Adverse Event	0	0	7
Overall Study	Disease progression	0	0	2
Overall Study	Lost to Follow-up	6	3	1
Overall Study	Non-compliance	3	0	2
Overall Study	Other	1	0	0
Overall Study	Physician Decision	0	0	2
Overall Study	Pregnancy	0	0	2
Overall Study	Protocol Violation	0	1	1
Overall Study	Requirement for alternative therapy	0	1	1
Overall Study	Withdrawal by Subject	2	3	5

Baseline characteristics

Characteristic	Etanercept 50 mg BIW	Total	Non-randomized	Etanercept 50 mg QW + Topical
Age, Continuous	45.7 years STANDARD_DEVIATION 13.1	45.3 years STANDARD_DEVIATION 13.9	36.6 years STANDARD_DEVIATION 11.2	46.3 years STANDARD_DEVIATION 14.6
Body Mass Index (BMI) ≤ 30	81 participants	174 participants	13 participants	80 participants
Body Mass Index (BMI) > 30	63 participants	136 participants	10 participants	63 participants
Prior anti-Tumor Necrosis Factor (TNF) Treatment Naive	116 participants	NA participants	NA participants	120 participants
Prior anti-Tumor Necrosis Factor (TNF) Treatment Prior exposure	24 participants	NA participants	NA participants	22 participants
Race/Ethnicity, Customized American Indian or Alaska Native	1 participants	1 participants	0 participants	0 participants
Race/Ethnicity, Customized Asian	14 participants	19 participants	0 participants	5 participants
Race/Ethnicity, Customized Mixed Race	1 participants	1 participants	0 participants	0 participants
Race/Ethnicity, Customized Other	8 participants	17 participants	1 participants	8 participants
Race/Ethnicity, Customized White	120 participants	272 participants	22 participants	130 participants
Sex: Female, Male Female	46 Participants	109 Participants	14 Participants	49 Participants
Sex: Female, Male Male	98 Participants	201 Participants	9 Participants	94 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk
deaths Total, all-cause mortality	— / —	— / —
other Total, other adverse events	65 / 177	62 / 133
serious Total, serious adverse events	4 / 177	0 / 133

Outcome results

Primary

Percent Change in Psoriasis Area and Severity Index (PASI) From Week 12 to Week 24

The Psoriasis Area and Severity Index (PASI) score is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from none (0), mild (1), moderate (2), severe (3) or very severe (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease. Change from Week 12 to Week 24 is presented as a percentage of the Week 12 value: Week 12 value - Week 24 value / Week 12 value \* 100 so that a positive change indicates improvement. Change was adjusted for treatment using a mixed model.

Time frame: Week 12 and Week 24

Population: Efficacy Evaluable set, which included all randomized participants who had taken at least 1 dose of study drug and had at least 1 post-randomization efficacy evaluation, and with available data at Week 12 and Week 24.

Arm	Measure	Value (LEAST_SQUARES_MEAN)	Dispersion
Etanercept 50 mg BIW	Percent Change in Psoriasis Area and Severity Index (PASI) From Week 12 to Week 24	17.02 percent change	Standard Error 7.06
Etanercept 50 mg QW + Topical	Percent Change in Psoriasis Area and Severity Index (PASI) From Week 12 to Week 24	0.86 percent change	Standard Error 7.06

95% CI: [-3.5, 35.82]

Secondary

Change From Baseline to Weeks 12 and 24 in Dermatology Quality of Life Index (DQLI) Total Score

The DLQI questionnaire asks participants to evaluate the degree that psoriasis has affected their quality of life in the last week, and includes the following parameters: symptoms and feelings, daily activities, leisure activities, work or school activities, personal relationships and treatment related feelings. Participants answer 10 questions on a scale from 0 (not at all) to 3 (very much); the range of the total score is 0 to 30. A score of 21 to 30 means an extremely large effect on the participant's life whereas 0-1 means that the disease has no effect at all. Change from Baseline was calculated as Baseline value - postbaseline value so that a positive change indicates improvement.

Time frame: Baseline and Week 12 and Week 24

Population: Full analysis set with available data; LOCF was used

Arm	Measure	Group	Value (MEAN)	Dispersion
Etanercept 50 mg BIW	Change From Baseline to Weeks 12 and 24 in Dermatology Quality of Life Index (DQLI) Total Score	Change at Week 12 (n=141, 139)	10.01 units on a scale	Standard Deviation 7.03
Etanercept 50 mg BIW	Change From Baseline to Weeks 12 and 24 in Dermatology Quality of Life Index (DQLI) Total Score	Change at Week 24 (n=135, 129)	10.71 units on a scale	Standard Deviation 7.8
Etanercept 50 mg QW + Topical	Change From Baseline to Weeks 12 and 24 in Dermatology Quality of Life Index (DQLI) Total Score	Change at Week 12 (n=141, 139)	9.71 units on a scale	Standard Deviation 6.15
Etanercept 50 mg QW + Topical	Change From Baseline to Weeks 12 and 24 in Dermatology Quality of Life Index (DQLI) Total Score	Change at Week 24 (n=135, 129)	9.87 units on a scale	Standard Deviation 6.91

Secondary

Change From Week 12 to Week 24 in Dermatology Quality of Life Index (DQLI) Total Score

The DLQI questionnaire asks participants to evaluate the degree that psoriasis has affected their quality of life in the last week, and includes the following parameters: symptoms and feelings, daily activities, leisure activities, work or school activities, personal relationships and treatment related feelings. Participants answer 10 questions on a scale from 0 (not at all) to 3 (very much); the range of the total score is 0 to 30. A score of 21 to 30 means an extremely large effect on the participant's life whereas 0-1 means that the disease has no effect at all. Change from Week 12 to Week 24 is calculated as: Week 12 value - Week 24 value so that a positive change indicates improvement. Change was adjusted for treatment using a mixed model.

Time frame: Week 12 and Week 24

Population: Efficacy Evaluable set with available data

Arm	Measure	Value (LEAST_SQUARES_MEAN)	Dispersion
Etanercept 50 mg BIW	Change From Week 12 to Week 24 in Dermatology Quality of Life Index (DQLI) Total Score	0.52 units on a scale	Standard Error 0.38
Etanercept 50 mg QW + Topical	Change From Week 12 to Week 24 in Dermatology Quality of Life Index (DQLI) Total Score	-0.03 units on a scale	Standard Error 0.39

Secondary

Change in Treatment Satisfaction Questionnaire for Medications (TSQM) Scores From Baseline to Weeks 12 and 24

The TSQM is a validated questionnaire consisting of 14 questions regarding a participant's perception of the level of satisfaction or dissatisfaction with the medication they are taking. Four scales are generated: side effects, effectiveness, convenience, and global satisfaction. Optional responses are: Extremely Dissatisfied, Very Dissatisfied, Dissatisfied, Somewhat Satisfied, Satisfied, Very Satisfied, and Extremely Satisfied. From the responses, a scale score from 0 - 100 is calculated, with a higher score indicating greater satisfaction. Change was calculated as postbaseline value - Baseline value so that a positive change indicates improvement.

Time frame: Baseline and Weeks 12 and 24

Population: Full analysis set; LOCF was used; n indicates the number of patients with available data for each scale at each time point.

Arm	Measure	Group	Value (MEAN)	Dispersion
Etanercept 50 mg BIW	Change in Treatment Satisfaction Questionnaire for Medications (TSQM) Scores From Baseline to Weeks 12 and 24	Week 12: Effectiveness (n=133, 129)	31.37 units on a scale	Standard Deviation 34.5
Etanercept 50 mg BIW	Change in Treatment Satisfaction Questionnaire for Medications (TSQM) Scores From Baseline to Weeks 12 and 24	Week 12: Convenience (n=132, 129)	15.87 units on a scale	Standard Deviation 26.86
Etanercept 50 mg BIW	Change in Treatment Satisfaction Questionnaire for Medications (TSQM) Scores From Baseline to Weeks 12 and 24	Week 12: Side effects (n=132, 125)	0.0 units on a scale	Standard Deviation 19.07
Etanercept 50 mg BIW	Change in Treatment Satisfaction Questionnaire for Medications (TSQM) Scores From Baseline to Weeks 12 and 24	Week 12: Global Satisfaction (n=133, 129)	31.10 units on a scale	Standard Deviation 32.99
Etanercept 50 mg BIW	Change in Treatment Satisfaction Questionnaire for Medications (TSQM) Scores From Baseline to Weeks 12 and 24	Week 24: Effectiveness (n=127, 120)	27.08 units on a scale	Standard Deviation 36.1
Etanercept 50 mg BIW	Change in Treatment Satisfaction Questionnaire for Medications (TSQM) Scores From Baseline to Weeks 12 and 24	Week 24: Convenience (n=127, 121)	14.83 units on a scale	Standard Deviation 25.88
Etanercept 50 mg BIW	Change in Treatment Satisfaction Questionnaire for Medications (TSQM) Scores From Baseline to Weeks 12 and 24	Week 24: Side effects (n=127, 119)	-0.74 units on a scale	Standard Deviation 22.04
Etanercept 50 mg BIW	Change in Treatment Satisfaction Questionnaire for Medications (TSQM) Scores From Baseline to Weeks 12 and 24	Week 24: Global Satisfaction (n=128, 120)	26.73 units on a scale	Standard Deviation 32.54
Etanercept 50 mg QW + Topical	Change in Treatment Satisfaction Questionnaire for Medications (TSQM) Scores From Baseline to Weeks 12 and 24	Week 24: Global Satisfaction (n=128, 120)	28.39 units on a scale	Standard Deviation 35.94
Etanercept 50 mg QW + Topical	Change in Treatment Satisfaction Questionnaire for Medications (TSQM) Scores From Baseline to Weeks 12 and 24	Week 12: Effectiveness (n=133, 129)	32.64 units on a scale	Standard Deviation 36.66
Etanercept 50 mg QW + Topical	Change in Treatment Satisfaction Questionnaire for Medications (TSQM) Scores From Baseline to Weeks 12 and 24	Week 24: Effectiveness (n=127, 120)	32.45 units on a scale	Standard Deviation 40.29
Etanercept 50 mg QW + Topical	Change in Treatment Satisfaction Questionnaire for Medications (TSQM) Scores From Baseline to Weeks 12 and 24	Week 12: Convenience (n=132, 129)	16.47 units on a scale	Standard Deviation 30.39
Etanercept 50 mg QW + Topical	Change in Treatment Satisfaction Questionnaire for Medications (TSQM) Scores From Baseline to Weeks 12 and 24	Week 24: Side effects (n=127, 119)	1.26 units on a scale	Standard Deviation 19.44
Etanercept 50 mg QW + Topical	Change in Treatment Satisfaction Questionnaire for Medications (TSQM) Scores From Baseline to Weeks 12 and 24	Week 12: Side effects (n=132, 125)	-0.15 units on a scale	Standard Deviation 20.75
Etanercept 50 mg QW + Topical	Change in Treatment Satisfaction Questionnaire for Medications (TSQM) Scores From Baseline to Weeks 12 and 24	Week 24: Convenience (n=127, 121)	18.53 units on a scale	Standard Deviation 29
Etanercept 50 mg QW + Topical	Change in Treatment Satisfaction Questionnaire for Medications (TSQM) Scores From Baseline to Weeks 12 and 24	Week 12: Global Satisfaction (n=133, 129)	27.09 units on a scale	Standard Deviation 32.48

Secondary

Change in Treatment Satisfaction Questionnaire for Medications (TSQM) Scores From Week 12 to Week 24

TSQM is a validated questionnaire consisting of 14 questions regarding a participant's perception of the level of satisfaction or dissatisfaction with the medication they are taking. Four scales are generated: side effects, effectiveness, convenience, and global satisfaction. Optional responses are: Extremely Dissatisfied, Very Dissatisfied, Dissatisfied, Somewhat Satisfied, Satisfied, Very Satisfied, and Extremely Satisfied. From the responses, a scale score from 0 - 100 is calculated, with a higher score indicating greater satisfaction. Change was calculated as Week 24 - Week 12 so that a positive change indicates improvement over time. Change was adjusted for treatment using a mixed model.

Time frame: Week 12 and Week 24

Population: Efficacy Evaluable with available data; n indicates the number of patients with available data for each scale.

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)	Dispersion
Etanercept 50 mg BIW	Change in Treatment Satisfaction Questionnaire for Medications (TSQM) Scores From Week 12 to Week 24	Effectiveness (n=135, 127)	-3.05 units on a scale	Standard Error 2.64
Etanercept 50 mg BIW	Change in Treatment Satisfaction Questionnaire for Medications (TSQM) Scores From Week 12 to Week 24	Convenience (n=135, 128)	-1.27 units on a scale	Standard Error 1.19
Etanercept 50 mg BIW	Change in Treatment Satisfaction Questionnaire for Medications (TSQM) Scores From Week 12 to Week 24	Side effects (n=135, 126)	-0.43 units on a scale	Standard Error 1.3
Etanercept 50 mg BIW	Change in Treatment Satisfaction Questionnaire for Medications (TSQM) Scores From Week 12 to Week 24	Global Satisfaction (n=135, 128)	-4.09 units on a scale	Standard Error 1.59
Etanercept 50 mg QW + Topical	Change in Treatment Satisfaction Questionnaire for Medications (TSQM) Scores From Week 12 to Week 24	Global Satisfaction (n=135, 128)	1.34 units on a scale	Standard Error 1.64
Etanercept 50 mg QW + Topical	Change in Treatment Satisfaction Questionnaire for Medications (TSQM) Scores From Week 12 to Week 24	Effectiveness (n=135, 127)	0.09 units on a scale	Standard Error 2.74
Etanercept 50 mg QW + Topical	Change in Treatment Satisfaction Questionnaire for Medications (TSQM) Scores From Week 12 to Week 24	Side effects (n=135, 126)	2.22 units on a scale	Standard Error 1.35
Etanercept 50 mg QW + Topical	Change in Treatment Satisfaction Questionnaire for Medications (TSQM) Scores From Week 12 to Week 24	Convenience (n=135, 128)	2.57 units on a scale	Standard Error 1.23

Secondary

Health Resource Utilization: Ability to Perform Daily Activities

Participants were asked: How much did your psoriasis affect your ability to do your daily activities or household chores? Possible answers were: a) A great deal; b) Quite a bit; c) Somewhat; d) Minimally; e) Not at all.